Genetic Diseases
Conditions
Interventions
PLACEBO
IMR 687
Sponsors
IMARA Inc
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Male or female aged =18 to =65 years at the time of informed consent form (ICF) signing. 2. Confirmed diagnosis of SCD (HbSS, HbSB0 thalassemia, or HbSB+ thalassemia) in the medical record; if not available, the diagnosis must be confirmed at the site’s local laboratory instead. 3. Subjects must have had at least 1 and no more than 12 documented episodes of VOC in the past 12 months at the time of ICF signing and at randomization (Day 1). For study eligibility, VOC is defined as a documented episode of an acute painful crisis (for which there was not an explanation other than VOC) that involved moderate to severe pain lasting for at least 2 hours and at least one of the following: • Use of escalated analgesia (including healthcare professional-instructed use of an analgesic prescription) • A hospital, emergency department, or clinic visit and/or healthcare telephone consultation at the time of occurrence • Diagnosis of acute chest syndrome (ACS) (defined as an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray), hepatic sequestration, or splenic sequestration 4. Hemoglobin (Hb) of >5.5 and <10.5 g/dL. 5. Absolute reticulocyte count =80 × 109 /L. 6. Subjects receiving HU must have received it continuously for at least 6 months prior to signing the ICF, and must have been on a stable dose for at least 3 months prior to signing the ICF, with no anticipated need for dose adjustments during the study including the screening period, in the opinion of the investigator. 7. Female subjects must not be pregnant or breastfeeding and be highly unlikely to become pregnant. Male subjects must be unlikely to impregnate a partner. Male or female subjects must meet at least one of the following criteria: • A female subject who is not of reproductive potential is eligible without requiring the use of contraception. A female subject who is not of reproductive potential is defined as one who: (1) has reached
Exclusion criteria
Exclusion criteria: 1. Hospital discharge for sickle cell crisis or other vaso-occlusive event within the 4 days prior to randomization (Day 1). 2. Red blood cell transfusion within 60 days of signing the ICF or on chronic transfusion therapy regimen. Transfusion status must be reassessed at randomization (Day 1). Note: If a subject requires a transfusion during the screening period, they may be rescreened up to one time. 3. Subjects with hereditary persistence of HbF (i.e., HbF >25% at screening). 4. Subjects with known active hepatitis A, hepatitis B, or hepatitis C, with active or acute event of malaria, or who are known to be positive for human immunodeficiency virus (HIV). 5. For female subjects of childbearing potential, a positive serum human chorionic gonadotropin (hCG) test (screening) or a positive urine hCG test at randomization (Day 1). 6. Estimated glomerular filtration rate (eGFR) 3 × the upper limit of normal. 8. Body mass index (BMI) 35 kg/m2 9. Current or history of malignancies (solid tumors and hematological malignancies), unless the subject has been free of the disease (including completion of any active or adjuvant treatment for prior malignancy) for =5 years. However, subjects with the following history/concurrent conditions are allowed if, in the opinion of the investigator, the condition has been adequately diagnosed and is determined to be clinically in remission, and the subject’s participation in the study would not represent a safety concern: a. Basal or squamous cell carcinoma of the skin b. Carcinoma in situ of the cervix c. Carcinoma in situ of the breast d. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis clinical staging system) A history of a clinically significant allergic reaction or hypersensitivity, as judged by the investigator, to any drug or any component of the study drug formulations used in the study (see Investigator’s Brochure). 11. History of unstable or deteriorating cardiac or pulmonary disease within 6 months before signing the ICF, including but not limited to the following: a. Unstable angina pectoris or myocardial infarction or elective coronary intervention b. Congestive heart failure requiring hospitalization c. Uncontrolled clinically significant arrhythmias 12. Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable). 13. On ECG testing at ICF signing and/or randomization (Day 1), a corrected QT interval, Fridericia’s formula (QTcF) >450 ms in men and >470 ms in women or the presence of clinically significant ECG abnormalities as determined by the investigator. 14. A history of major surgery within 4 weeks or minor surgery within 2 weeks of randomization (Day 1). 15. Stroke requiring medical intervention within 24 weeks prior to randomization (Day 1). 16. Subjects taking direct acting oral anti-coagulants (DOACs) apixaban, dabigatran, rivaroxaban, edoxaban, or ticagrelor, or taking warfarin, are excluded due to the possibility of a cytochrome P450 (CYP)3A-mediated drug interaction, unless they stopped the treatment at least 28 days prior to randomization (Day 1); other oral anti-c
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Objectives • To evaluate the fetal hemoglobin (HbF) response to IMR-687 versus placebo • To evaluate the safety of IMR-687 versus placebo | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the effect of IMR-687 versus placebo on HbF-associated biomarkers • To evaluate the effect of IMR-687 versus placebo on indices of red cell hemolysis • To evaluate the effect of IMR-687 versus placebo on indices of white blood cell (WBC) adhesion • To evaluate the effect of IMR-687 versus placebo on the incidence of vaso-occlusive crises (VOCs) • To evaluate the effect of IMR-687 versus placebo on quality of life measures | — |
Countries
Egypt, Ghana, Kenya, Morocco, Senegal, Tunisia, Uganda
Contacts
Public ContactLynda Mante
Clinical Project Lead on the Study
Outcome results
None listed